1832 Asset Management L.P. Increases Holdings in Becton, Dickinson and Company $BDX

1832 Asset Management L.P. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 305,950 shares of the medical instruments supplier’s stock after buying an additional 27,760 shares during the quarter. 1832 Asset Management L.P. owned about 0.11% of Becton, Dickinson and Company worth $70,081,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock worth $18,808,000 after purchasing an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $6,406,000. GAMMA Investing LLC increased its holdings in shares of Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after purchasing an additional 748 shares in the last quarter. Finally, Ritholtz Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $224,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares of the company’s stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Claire Fraser sold 863 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the sale, the director directly owned 23,143 shares of the company’s stock, valued at $4,450,398.90. This represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,214 shares of company stock valued at $579,206. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $199.5030 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The firm has a market capitalization of $57.18 billion, a P/E ratio of 35.88, a PEG ratio of 1.47 and a beta of 0.20. The business has a fifty day moving average of $180.65 and a 200 day moving average of $195.60.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the company posted $3.50 earnings per share. Becton, Dickinson and Company’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Analyst Ratings Changes

A number of analysts have commented on the company. Citigroup lowered Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their target price for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. William Blair lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Thursday, May 1st. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price for the company. in a report on Thursday, May 1st. Finally, Raymond James Financial lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. Four research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.